Rituximab biosimilar by Celltrion for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Rituximab biosimilar is under clinical development by Celltrion and is currently in the Phase II in clinical pathway.

Source link
#Rituximab #biosimilar #Celltrion #Waldenstrom #Macroglobulinemia #Lymphoplasmacytic #Lymphoma #Likelihood #Approval